{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"marrow CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"hematologic improvement of at least 1 lineage"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Number of participants with efficacy measures other than CR as defined by modified IWG criteria (2006) in LIC, including marrow CR(mCR), stable disease(SD), hematologic improvement(HI). CR: hemoglobin≥11 g/dL, neutrophils≥1 x 10\\^9/L, platelets≥1 x 10\\^11/L, percentage of blasts=0%, percentage of BMB≤5%, normal maturation of all cell lines (note if has persistent dysplasia), all responses last at least 4 weeks. mCR: BMB≤5% \\& decreased by≥50%. SD: failure to achieve PR, no evidence of progression. HI: erythroid response (pretreatment\\<11g/dL): hemoglobin increase by≥1.5 g/dL, relevant reduction of units of red blood cell transfusions by at least 4 transfusions/8 weeks compared to pretreatment transfusion number in previous 8 weeks; platelet response (pretreatment\\<1x10\\^11/L): increase of≥30x10\\^9/L if starting with \\>20x10\\^9/L, and increase from \\<20x10\\^9/L to \\>20x10\\^9/L and by at least 100%; neutrophil response (pretreatment\\<1x10\\^9/L): at least a 100% increase, absolute increase \\>0.5x10\\^9/L","groups":[{"description":"Participants received SC administration of azacitidine daily at a dose of 75 mg/m2/day on Days 1-7 of every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD. In Cycle 1 only, administration of glasdegib commenced on Day 2 of the cycle (C1D2) to permit DDI evaluation.","id":"OG000","title":"Lead-in Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis set was defined as all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of approximately 16 months","title":"Number of Participants With Efficacy Measures Other Than CR in the LIC","type":"SECONDARY","unitOfMeasure":"Participants"}